News Releases Keyword search Year None202220212020201920182017201620152014201320122011201020092008 12/27/2022 AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock 12/8/2022 AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine 11/14/2022 AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 11/3/2022 AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 10/31/2022 AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 10/27/2022 AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant 10/26/2022 AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 10/25/2022 AcelRx Pharmaceuticals Announces Reverse Stock Split 10/25/2022 AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences 9/6/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Print Page RSS Feeds
Keyword search Year None202220212020201920182017201620152014201320122011201020092008 12/27/2022 AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock 12/8/2022 AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine 11/14/2022 AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 11/3/2022 AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 10/31/2022 AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 10/27/2022 AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant 10/26/2022 AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 10/25/2022 AcelRx Pharmaceuticals Announces Reverse Stock Split 10/25/2022 AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences 9/6/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
12/27/2022 AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
12/8/2022 AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
11/14/2022 AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10/31/2022 AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022
10/26/2022 AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022
10/25/2022 AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences
